uniQure is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients
with severe disorders.
We believe our multiple partnerships and the regulatory approval of our lead product Glybera in the European Union for a subset of patients with LPLD provides validation for our approach .
A phase I/II gene therapy clinical trial for children suffering from Sanfilippo B syndrome, a rare genetic disease, enrolled a first patient in October of this year.
uniQure Announces Confidential Submission of Draft Registration Statement for Initial Public Offering
uniQure B.V., a leader in human gene therapy, today announced that Christian Meyer, M.D., Ph.D., has joined the company as Chief Medical Officer.
uniQure B.V. has been named by FierceBiotech as one of 2013’s Fierce 15 biotechs, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech’s eleventh annual Fierce 15 selection.
uniQure to build 55,000 square foot state-of-the-art gene therapy production plant in US to leverage AAV-manufacturing strength